Advertisement

Topics

ASCO 2018: Shorter trastuzumab treatment for HER2 positive breast cancer can be as effective, with fewer cardiac side effects

10:57 EDT 17 May 2018 | ecancermedicalscience

A phase III randomized clinical trial of 4,088 women with HER2-positive, early-stage breast cancer found that taking trastuzumab (Herceptin) for 6 months was non-inferior to the current standard of 12 months. The disease-free survival rate at four years...

Original Article: ASCO 2018: Shorter trastuzumab treatment for HER2 positive breast cancer can be as effective, with fewer cardiac side effects

NEXT ARTICLE

More From BioPortfolio on "ASCO 2018: Shorter trastuzumab treatment for HER2 positive breast cancer can be as effective, with fewer cardiac side effects"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...